Li Szu-Yuan, Yang Wu-Chang, Chuang Chiao-Lin
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan.
Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan.
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1628-33. doi: 10.1016/j.jtcvs.2014.05.006. Epub 2014 May 6.
Continuous renal replacement therapy (CRRT) is currently the mainstay renal support for critically ill patients. However, the optimal intensity of CRRT remains debated owing to the heterogeneity of the study populations and CRRT techniques across centers. The present study investigated the beneficial effects of early and intensive continuous venovenous hemofiltration (CVVH) on patients with shock after cardiotomy.
Patients who had received CRRT for cardiogenic shock and acute kidney injury after cardiac surgery from January 2003 to December 2007 were retrospectively recruited. They were divided into 2 groups according to the delivered dosage of hemofiltration.
The mean duration between intensive care unit admission and initiation of CVVH was 1.4±0.8 days. The all-cause mortality by day 30 was 73.3% and 45.4% in the low- and high-dose groups, respectively (P=.002). The corresponding in-hospital mortality rate was 82.2% and 61.8% (P=.02). No significant difference was seen in the renal recovery of the survivors between the 2 groups.
In patients developing postoperative cardiogenic shock and acute kidney injury after cardiac surgery, an early higher CVVH dose was associated with better in-hospital and long-term survival. Moreover, the beneficial effect of intensive treatment might be more critical in the early perioperative period.
连续性肾脏替代治疗(CRRT)目前是重症患者主要的肾脏支持治疗方式。然而,由于各中心研究人群和CRRT技术的异质性,CRRT的最佳强度仍存在争议。本研究探讨早期强化连续性静脉-静脉血液滤过(CVVH)对心脏手术后休克患者的有益作用。
回顾性纳入2003年1月至2007年12月因心源性休克和心脏手术后急性肾损伤接受CRRT治疗的患者。根据血液滤过的实施剂量将他们分为两组。
重症监护病房入院至开始CVVH的平均时间为1.4±0.8天。低剂量组和高剂量组第30天的全因死亡率分别为73.3%和45.4%(P = 0.002)。相应的住院死亡率分别为82.2%和61.8%(P = 0.02)。两组幸存者的肾脏恢复情况无显著差异。
在心脏手术后发生术后心源性休克和急性肾损伤的患者中,早期较高的CVVH剂量与更好的住院和长期生存相关。此外,强化治疗的有益效果在围手术期早期可能更为关键。